The New Frontier of Combination Therapy for IBD: The VEGA RCT Tarun Chhibba, MD1 and Bharati  Kochar, MD, MS2  1Advanced…

In Case You Missed It Biosimilar BI 695501 Has Similar Safety and  Efficacy To Adalimumab for the Treatment of Crohn’s…

Upadacitinib Is Effective for the Induction and Maintenance of Moderate-to-Severe Crohn’s  Disease Rahul S. Dalal, MD, MPH1 and Jessica R.…

Vedolizumab: An EARNEST Option for the Management of Chronic Pouchitis Kristin E. Burke, MD, MPH1,2 and Bharati Kochar, MD, MS…

SEAVUE: A Sea of Change in Biologic Positioning for Crohn’s Disease Bharati Kochar, MD, MS Division of Gastroenterology, Massachusetts General…

In Case You Missed It Vedolizumab Is Superior to Adalimumab for Clinical Remission and Endoscopic Improvement of Ulcerative Colitis: The…

ACG EBGI: This Evidence-based summary looks at D’Haens G, Panaccione R, Baert F, et al. Risankizumab as Induction Therapy for Crohn’s Disease: Results from the Phase 3 ADVANCE and MOTIVATE Induction Trials. Lancet 2022;399(10340):2015-30.

ACG EBGI: Evidence-based summary reviews Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal Phase 3 FORTIFY maintenance trial. Lancet 2022;399(10340):2031-2046.

Ozanimod for Moderate-Severe Ulcerative Colitis: Rethinking the Top-Down Treatment Algorithm Oriana Damas, MD1 and Philip Schoenfeld, MD, MSEd, MSc (Epi)2…

Continuing Anti-TNF Agents Past 24 Weeks of Pregnancy Associated with Fewer IBD Relapses with No Increase in Adverse Fetal Outcomes…